B. Riley analyst Bryan Maher lowered the firm’s price target on Alerislife to $1.50 from $2 and keeps a Neutral rating on the shares following the "mixed" Q3 results.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALR: